Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience

被引：2

作者：

Al jarroudi, Ouissam ^{[1
,2
,3
]}

Chaabouni, Hamed ^{[1
]}

Ulusakarya, Ayhan ^{[1
]}

Almohamad, Wathek ^{[1
]}

Gumus, Yusuf ^{[1
]}

Goldschmidt, Emma ^{[1
]}

Afqir, Said ^{[2
,3
]}

Morere, Jean-francois ^{[1
]}

机构：

[1] Hop Paul Brousse, AP HP, Med Oncol Dept, Villejuif, France

[2] Univ Hosp Mohammed VI Oujda, Med Oncol Dept, Oujda, Morocco

[3] Mohammed Ist Univ, Fac Med & Pharm, Oujda, Morocco

来源：

CLINICAL CASE REPORTS | 2021年 / 9卷 / 04期

关键词：

clinical outcomes; hepatocellular carcinoma; nivolumab; survival;

D O I：

10.1002/ccr3.3970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nivolumab is an effective and safe treatment in HCC.

引用

页码：2162 / 2167

页数：6

共 35 条

[1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma [J].

Abou-Alfa, G. K. ;

Meyer, T. ;

Cheng, A. -L. ;

El-Khoueiry, A. B. ;

Rimassa, L. ;

Ryoo, B. -Y. ;

Cicin, I. ;

Merle, P. ;

Chen, Y. H. ;

Park, J. -W. ;

Blanc, J. -F. ;

Bolondi, L. ;

Klumpen, H. -J. ;

Chan, S. L. ;

Zagonel, V. ;

Pressiani, T. ;

Ryu, M. -H. ;

Venook, A. P. ;

Hessel, C. ;

Borgman-Hagey, A. E. ;

Schwab, G. ;

Kelley, R. K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) :54-63

[2] Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience [J].

Al jarroudi, Ouissam ;

Chaabouni, Hamed ;

Ulusakarya, Ayhan ;

Almohamad, Wathek ;

Gumus, Yusuf ;

Goldschmidt, Emma ;

Afqir, Said ;

Morere, Jean-francois .

CLINICAL CASE REPORTS, 2021, 9 (04) :2162-2167

[3] Rules of recruitment for Th1 and Th2 lymphocytes in inflamed liver: A role for alpha-4 integrin and vascular adhesion protein-1 [J].

Bonder, CS ;

Norman, MU ;

Swain, MG ;

Zbytnuik, LD ;

Yamanouchi, J ;

Santamaria, P ;

Ajuebor, M ;

Salmi, M ;

Jalkanen, S ;

Kubes, P .

IMMUNITY, 2005, 23 (02) :153-163

[4] Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[5] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[6] New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy [J].

Chan, Stephen L. ;

Mo, Frankie K. F. ;

Johnson, Philip J. ;

Hui, Edwin P. ;

Ma, Brigette B. Y. ;

Ho, Wing M. ;

Lam, Kwok C. ;

Chan, Anthony T. C. ;

Mok, Tony S. K. ;

Yeo, Winnie .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (03) :446-452

[7]

Child C G, 1964, Major Probl Clin Surg, V1, P1

[8] Comparison of hepatocellular carcinoma in Eastern versus Western populations [J].

Choo, Su Pin ;

Tan, Wan Ling ;

Goh, Brian K. P. ;

Tai, Wai Meng ;

Zhu, Andrew X. .

CANCER, 2016, 122 (22) :3430-3446

[9] Cancer-related inflammation and treatment effectiveness [J].

Diakos, Connie I. ;

Charles, Kellie A. ;

McMillan, Donald C. ;

Clarke, Stephen J. .

LANCET ONCOLOGY, 2014, 15 (11) :E493-E503

[10] Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].

El-Khoueiry, Anthony B. ;

Sangro, Bruno ;

Yau, Thomas ;

Crocenzi, Todd S. ;

Kudo, Masatoshi ;

Hsu, Chiun ;

Kim, Tae-You ;

Choo, Su-Pin ;

Trojan, Jorg ;

Welling, Theodore H., III ;

Meyer, Tim ;

Kang, Yoon-Koo ;

Yeo, Winnie ;

Chopra, Akhil ;

Anderson, Jeffrey ;

dela Cruz, Christine ;

Lang, Lixin ;

Neely, Jaclyn ;

Tang, Hao ;

Dastani, Homa B. ;

Melero, Ignacio .

LANCET, 2017, 389 (10088) :2492-2502

← 1 2 3 4 →